Bullish
Cencora's role in the U.S. healthcare market is being shaped by specialty drug demand, healthcare distribution, working capital discipline, margin con...
/Cencora%20Inc_%20HQ-by%20JHVEPhoto%20via%20iStock.jpg)
Neutral
Cencora, Inc. (COR) is underperforming the Nasdaq Composite, with its stock declining significantly over the past three months and year-to-date. This ...
Pomerantz LLP is investigating potential claims on behalf of investors of Cencora, Inc. (NYSE: COR) following a significant drop in its stock price. T...
Cencora has partnered with Kite to manage the US distribution of Yescarta and Tecartus, aiming to expand access and streamline the commercialization o...
Cencora's Independent Chairman of the Board, Mark M. Durcan, recently purchased US$1.1 million worth of shares, increasing his holding by 17%. While t...
Neutral
National Pension Service lifted its position in Cencora, Inc. (NYSE:COR – Free Report) by 6.3% in the fourth quarter, according to its most recent For...
Cencora (COR) has recently experienced a significant share price decline, down 13% over the past month and 28% in three months, though long-term holde...
Bullish
Cencora Inc. has appointed Eva C. Boratto as its new Executive Vice President and CFO, effective June 29, 2026, succeeding James F. Cleary. The compan...
Bullish
Cencora Inc. has appointed its former CEO, Steven Collis, as the new chair of the board shortly after his departure as chief executive. This leadershi...
Neutral
Cencora Inc. has updated its fiscal year 2026 financial outlook, modestly raising its adjusted earnings guidance and authorizing an additional $2 bill...
Bullish
Cencora, formerly AmerisourceBergen, is undergoing a strategic transformation with solid earnings and guidance, maintaining its position as a key phar...
Bearish
Cencora (US15135B1017) faced a Q2 2026 revenue miss, reduced guidance, and a significant stock drop, leading to a shareholder investigation. The compa...
Bullish
Latitude Investment Management's Q4 2025 investor letter highlights Cencora (NYSE: COR) as a strong performer, driven by robust fundamentals and a str...
Neutral
Wells Fargo maintained its Overweight rating on Cencora (COR) but lowered its price target to $331 from $429 due to disappointing U.S. healthcare earn...